ELTX Overview

Trial Results: Elicio Therapeutics announced that 99% of patients in its Phase 2 AMPLIFY-7P trial showed strong mKRAS-specific T cell responses after treatment with the investigational cancer vaccine ELI-002 7P, with immune responses increasing 145-fold from baseline.

Future Expectations: The company anticipates final disease-free survival data from the trial by the fourth quarter of 2025, and an independent monitoring committee has recommended that the trial continue without changes, indicating potential efficacy.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders succeed in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

Elicio Therapeutics KOL Event: Elicio Therapeutics will host a virtual event on June 25, 2025, to discuss the treatment landscape for mutant-KRAS driven pancreatic cancer, featuring insights from leading experts and focusing on their lead product candidate, ELI-002, which is currently in a Phase 2 trial.

ELI-002 and AMP Platform: ELI-002 is an investigational cancer vaccine targeting KRAS mutations, utilizing Elicio's proprietary amphiphile (AMP) platform designed to enhance immune responses by delivering therapeutics directly to lymph nodes, with plans for future expansion into other cancer indications.

Funding Announcement: Elicio Therapeutics has secured a $10 million senior secured promissory note to support operations until Q1 2026, coinciding with the anticipated interim analysis of their AMPLIFY-7P Phase 2 trial in Q3 2025.

Product Development: The company is advancing its lead cancer vaccine candidate, ELI-002, targeting mKRAS-driven tumors, and plans to explore additional indications and combination therapies for pancreatic and colorectal cancers.